SARS-CoV-2 challenge studies: ethics and risk minimisation
COVID-19 poses an exceptional threat to global public health and well-being. Recognition of the need to develop effective vaccines at unprecedented speed has led to calls to accelerate research pathways ethically, including by conducting challenge studies (also known as controlled human infection st...
Main Authors: | Bull, S, Jamrozik, E, Binik, A, Parker, MJ |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BMJ Publishing Group
2020
|
Similar Items
-
Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies
by: Bastian Steuwer, et al.
Published: (2021-04-01) -
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.
by: Antonio Muruato, et al.
Published: (2021-11-01) -
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
by: Antonio Muruato, et al.
Published: (2021-11-01) -
Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward
by: Vipin M. Vashishtha, et al.
Published: (2021-06-01) -
Comparison between SARS-CoV and SARS-CoV 2
by: Fang Meng
Published: (2021-01-01)